Fingerprint
Dive into the research topics of 'Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi*, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil-Gil, Wei Li, Jean Yves Pierga, Seock Ah Im, Halle C.F. Moore
*Corresponding author for this work
- Memorial Sloan-Kettering Cancer Center
- Université de Montpellier
- Kanagawa Cancer Center Research Institute
- Yonsei University
- Hospital Clinic Barcelona
- National Hospital Organization Kyushu Cancer Center
- Showa University
- University of Texas MD Anderson Cancer Center
- August Pi i Sunyer Biomedical Research Institute
- University of Barcelona
- IOB Institute of Oncology
- Kyungpook National University
- National Cancer Center Korea
- Tokai University
- Samsung Medical Center, Sungkyunkwan university
- Chinese Academy of Medical Sciences
- Zhejiang Cancer Hospital
- Institute Catala Oncologia
- The First Hospital of Jilin University
- Université Paris Cité
- Seoul National University
- Cleveland Clinic Foundation
- University of California at San Francisco
- Athens General Hospital
- Université libre de Bruxelles
- University of Ulsan
- Sun Yat-Sen University
- Sichuan University
- Vall d'Hebron Institute of Oncology
- Queen Mary University of London
- Liaoning Tumor Hospital & Institute
- Daiichi Sankyo Company, Limited
- Ludwig Maximilian University of Munich
- University of Edinburgh
Research output: Contribution to journal › Article › peer-review
1672
Scopus
citations